Jack Slevin
Stock Analyst at Jefferies
(3.99)
# 1,821
Out of 4,683 analysts
42
Total ratings
58.6%
Success rate
20.4%
Average return
Main Sectors:
Stocks Rated by Jack Slevin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MD Pediatrix Medical Group | Downgraded: Hold | $27 → $28 | $26.95 | +3.90% | 5 | Aug 19, 2026 | |
| CVSA Covista | Reiterated: Buy | $175 | $137.78 | +27.01% | 5 | Aug 17, 2026 | |
| AHCO AdaptHealth | Upgraded: Buy | $13 | $5.67 | +129.28% | 1 | Jul 21, 2026 | |
| LFST LifeStance Health Group | Maintained: Buy | $14 | $12.15 | +15.23% | 1 | Jul 16, 2026 | |
| ASTH Astrana Health | Reiterated: Buy | $37 → $53 | $38.61 | +37.27% | 9 | Jun 30, 2026 | |
| AGL agilon health | Upgraded: Buy | $28 → $48 | $95.74 | -49.86% | 8 | May 7, 2026 | |
| USPH U.S. Physical Therapy | Rated: Buy | $102 | $78.27 | +30.32% | 1 | Mar 9, 2026 | |
| PRVA Privia Health Group | Reiterated: Buy | $30 → $32 | $21.07 | +51.87% | 6 | Feb 26, 2026 | |
| AMN AMN Healthcare Services | Maintained: Hold | $22 → $21 | $34.24 | n/a | 4 | Aug 13, 2025 | |
| STLN Starling Oncology | Maintained: Buy | $2.5 → $2 | $6.56 | n/a | 2 | Jun 10, 2024 |
Pediatrix Medical Group
Aug 19, 2026
Downgraded: Hold
Price Target: $27 → $28
Current: $26.95
Upside: +3.90%
Covista
Aug 17, 2026
Reiterated: Buy
Price Target: $175
Current: $137.78
Upside: +27.01%
AdaptHealth
Jul 21, 2026
Upgraded: Buy
Price Target: $13
Current: $5.67
Upside: +129.28%
LifeStance Health Group
Jul 16, 2026
Maintained: Buy
Price Target: $14
Current: $12.15
Upside: +15.23%
Astrana Health
Jun 30, 2026
Reiterated: Buy
Price Target: $37 → $53
Current: $38.61
Upside: +37.27%
agilon health
May 7, 2026
Upgraded: Buy
Price Target: $28 → $48
Current: $95.74
Upside: -49.86%
U.S. Physical Therapy
Mar 9, 2026
Rated: Buy
Price Target: $102
Current: $78.27
Upside: +30.32%
Privia Health Group
Feb 26, 2026
Reiterated: Buy
Price Target: $30 → $32
Current: $21.07
Upside: +51.87%
AMN Healthcare Services
Aug 13, 2025
Maintained: Hold
Price Target: $22 → $21
Current: $34.24
Upside: n/a
Starling Oncology
Jun 10, 2024
Maintained: Buy
Price Target: $2.5 → $2
Current: $6.56
Upside: n/a